Poxel, SA: Series A $20.3M

Posted in I - Series A, Q - 3Q10, R - INTERNATIONAL, X - Diabetes, X - Metabolism

Poxel (France) a clinical-stage small molecule company focused on Type-2 diabetes and metabolic disease, closed a $20.3M Series A financing. Participants include Edmond de Rothschild Investment Partners, InnoBio Ventures and Crédit Agricole Private Equity.

Swift Biosciences, Inc.: Series A $3M

Posted in I - Series A, Q - 3Q10, R - MID WEST, X - Reagent, XX - MI

Swift Biosciences (Ann Arbor, MI) a development-stage company focused on molecular biology reagents for R&D and diagnostics, closed a $3M Series A financing. Participants include DFJ Mercury.

Visterra, Inc.: Series A $6M

Posted in I - Series A, Q - 3Q10, R - NORTH WEST, X - Antiviral, X - Influenza, X - Vaccines, XX - MA

Visterra (Cambridge, MA) a development-stage company focused virus-glycan docking to derive products for the prevention, treatment and diagnosis of influenza and other infectious diseases, closed a $6M Series A financing. Participants include Flagship Ventures, Lux Capital and Polaris Venture Partners.

Calithera Biosciences, Inc.: Series A $40M

Posted in I - Series A, Q - 3Q10, R - WEST, X - Caspase, X - Oncology

Calithera Biosciences (San Francisco, CA) a preclinical-stage small molecule company focused on caspase activators for oncologic applications, closed a $40M Series A financing. Participants include Morgenthaler Ventures, U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital.

Ensysce Biosciences, Inc.: Series A $1.5M

Posted in I - Series A, Q - 2Q10, R - SOUTH WEST, X - Device (Delivery), XX - TX

Ensysce Biosciences (Houston, TX) a development-stage biopharma company focused on carbon nanotube complexes for chemotherapeutic transport, closed a $1.5M Series A financing. Participants include Texas Emerging Technology Fund.

NanoPowers, SA: Series A $4.5M

Posted in I - Series A, Q - 2Q10, R - INTERNATIONAL, X - Device (Urology)

NanoPowers (Switzerland) a development-stage medical device company focused on urinary incontinence, closed a $4.5M Series A financing. Participants include Novartis Venture Funds, Initiative Capital Romandie and Gran Plasa.

SynapDx Corp.: Series A $9M

Posted in I - Series A, Q - 2Q10, R - NORTH EAST, X - Autism, X - Device (Diagnostic), XX - MA

SynapDx (Waltham, MA) a development-stage diagnostic company focused on the early detection of autism, closed a $9M Series A financing. Participants include Bain Capital Ventures, General Catalyst Partners and North Bridge Venture Partners.

Reinnervate, Ltd.: Series A $2M

Posted in I - Series A, Q - 2Q10, R - INTERNATIONAL, X - Cell Culture

Reinnervate (United Kingdom) a development-stage company focused on in vitro cell culture technologies, closed a $2M Series A financing. Participants include NorthStar Equity Investors.

Palmaz Scientific, Inc.: Series A $3M

Posted in I - Series A, Q - 2Q10, R - SOUTH WEST, X - Biomaterial, XX - TX

Palmaz Scientific (Dallas, TX) a development-stage nano-biomaterials company focused on a vapor deposition process to increase the reliability of implantable prosthetic devices, closed a $3M Series A financing. Participants include Texas Emerging Technology Fund.

Mirina Corp.: Series A $3.9M

Posted in I - Series A, Q - 2Q10, R - NORTH WEST, X - Oncology, X - RNAi, XX - WA

Mirina (Seattle, WA) a development-stage biotechnology company focused on miRNA therapeutics for oncology and metabolic disorders, closed a $3.9M Series A financing, bringing the total round to $7.5M. Participants include Versant Ventures, Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital.

« Previous Entries

to top of page...